A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company ...

MADRID (Reuters) -A New York court has found enough evidence to proceed with a defamation lawsuit filed by Grifols against ...

Grifols (GRFS) secures a win in its defamation lawsuit against Gotham City Research in the U.S. Read more here.

Health Minister Khaled Abdel Ghaffar met on Sunday, June 1st, 2025, with Magdy Amin, Chairman of Grifols Egypt, to discuss expanding cooperation in haematology and the national plasma derivatives ...

But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank ...

Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ: GRFS) class A ...

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

ADMA Biologics ADMA and Grifols GRFS are leading producers of plasma-derived therapies, specializing in immunoglobulin treatments for immunodeficiencies and other conditions. ADMA Biologics ...

MADRID (Reuters) -A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said ...